IDRX-42

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

IDRX-42 (formerly M4205) is a highly selective small molecule KIT inhibitor compound developed for the treatment of gastrointestinal stromal tumors. The compound was originally discovered by the German company Merck and later out-licensed to IDRX. In November 2024, promising anti-tumor data from ongoing Phase 1/1B studies were reported. In January 2025, the compound played a key role in the $1 billion acquisition of IDRX by GSK.

IDRX-42 (formerly M4205) is a highly selective small molecule KIT inhibitor compound developed for the treatment of gastrointestinal stromal tumors. The compound was originally discovered by the German company Merck and later out-licensed to IDRX. In November 2024, promising anti-tumor data from ongoing Phase 1/1B studies were reported. In January 2025, the compound played a key role in the $1 billion acquisition of IDRX by GSK.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1330313042 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

2 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.